Xi Cheng

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Julio Rosenstock, Ronnie Aronson, George Grunberger et al. · Diabetes Care · 2016 · 268 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

Shifu Xiao, Piu Chan, Tao Wang et al. · Alzheimer s Research & Therapy · 2021 · 202 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Low-dose aspirin increases aspirin resistance in patients with coronary artery disease

Pui‐Yin Lee, Wai‐Hong Chen, William Ng et al. · The American Journal of Medicine · 2005 · 184 citations

Medicine, Cardiology, Pharmacology +14

Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease

Wai‐Hong Chen, Xi Cheng, Pui‐Yin Lee et al. · The American Journal of Medicine · 2007 · 181 citations

Medicine, Cardiology, Pharmacology +16

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial ( <scp>EDITION JP</scp> 2)

Yasuo Terauchi, Masayoshi Koyama, Xi Cheng et al. · Diabetes Obesity and Metabolism · 2015 · 106 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17